Four women with periodontitis received intermittent cyclical etidronate (etidronate administered orally at a dose of 200 mg/day for 2 weeks, at intervals of 10 -12 weeks or 6 months) for 4 -5 years in addition to ordinary dental therapy. Alveolar bone density was measured using a new method comparing the percentage increase in density. Mean alveolar bone density increased significantly during intermittent cyclical etidronate treatment. Significant reductions were observed in the mobility of the teeth and the depth of periodontal pockets. There were significant correlations between alveolar bone density and both mobility of the teeth and the depth of the alveolar pockets. It is concluded that increases in alveolar bone density are associated with the clinical benefits of etidronate in the treatment of periodontitis.
Introduction
In a previous report we demonstrated that the bisphosphonate etidronate is effective in ameliorating tooth instability, decreasing the depth of pockets around the teeth and reducing other inflammatory symptoms in patients with periodontal disease. 1 Alveolar bone shows osteoporotic changes as one manifestation of generalized osteoporosis. Jeffcoat and colleagues 2 demonstrated that lumbar vertebral bone mineral density (BMD) correlates closely with the BMD of alveolar bones measured on X-ray films. In addition, Jonasson and co-workers 3 showed a significant correlation between the cervical thickness of the mandibular alveolar process and the skeletal BMD. These local changes in alveolar bone are accelerated by dental inflammation.
The inflammatory processes associated with bacterial periodontitis involve the increased production of cytokines that accelerate bone resorption, including tumour necrosis factor, interleukin (IL)-1 and IL-6. 4 Bisphosphonates, which bind to bone tissue and osteoclasts and suppress bone resorption, should therefore be effective in treating osteoporosis of alveolar bone occurring as part of systemic osteoporosis, as well as local bone resorption induced by inflammation of the periodontal tissues.
Jeffcoat and Reddy 5 showed that the bisphosphonate alendronate suppresses the resorption of bone in the alveolar pockets and whole jaw in periodontal disease. We have previously reported the effects of intermittent cyclical etidronate (ICE) administered to four patients with periodontal disease for 2 -3 years in addition to ordinary dental treatment for periodontitis. 1 This present study describes the results of following these same patients for an additional 2 -3 years.
Patients and methods

PATIENTS
We assessed the effect of ICE treatment (etidronate administered orally at a dose of 200 mg/day for 2 weeks, at intervals of 10 -12 weeks or 6 months) on the clinical manifestations of periodontitis and on alveolar bone density in four women with no history of systemic disease who were seen at the Takaishi Dental Clinic, Himeji, Japan. The Institutional Review Board approved the study. Written informed consent was obtained from the patients.
CLINICAL EXAMINATION
Clinical examination included measurement of the depth of the periodontal pockets and an assessment of the stability of the teeth. The mobility of each tooth was scored as follows: 1, movement of the top of the tooth of 0.2 -1.0 mm in the horizontal direction; 2, movement of more than 1.0 mm in the horizontal direction; and 3, movement in both the horizontal and vertical directions. The average of these scores was calculated to give an overall mobility score. 6 Panoramic X-ray films were taken at various intervals, and assessed for evidence of pathological changes, and the bone density was determined as outlined below. Statistical differences were determined by either correlation analysis (Table 1) or Scheffé test (Table 2 ). A P < 0.05 was considered statistically significant.
MEASUREMENT OF BONE DENSITY
The panoramic X-ray films of the jaw were scanned into a computer. The images were adjusted to eliminate differences in the mean values for brightness and variance using image-editing software (Adobe ® Photoshop ® , Adobe Systems Inc., San Jose, CA, USA), and then used to measure the density of the root of the mandibular first premolar. Although alveolar bone density is influenced by mastication, 3 the mandibular first premolar is believed to be the least affected by mastication in humans, as in rats, 7 and the apex of the root area has been reported to be the most suitable for measuring bone density. 8 A line was drawn at the apex of the root, parallel with the line of the cement-enamel junction. Another line, halfway between the cement-enamel junction and the apex of the root, was drawn. Lines were then drawn perpendicular to these lines at the medial and distal spaces of the first premolar. The X-ray film density in the area of the resulting rectangles ( Fig. 1) was measured by first dividing the area into pixels with sides 1/1524 cm in length. The brightness in each pixel was then compared with a scale consisting of 256 steps of brightness. The percentage brightness in each rectangle was measured before and at various times during treatment. First, percentage of pixels was plotted against level of brightness. To calculate the percentage brightness across the area of the rectangle, the number of pixels at each level of brightness was divided by the total number of pixels. 
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Case Reports PATIENT 1
On 17 June 1997, a 49-year-old woman presented with swelling of the right maxillary second molar due to alveolar abscess and impaired chewing because of instability of all of the teeth. At the first visit, an incision was made in the gingival portion of the right second maxillary molar, and antibiotics and anti-inflammatory analgesics were prescribed. Instruction was given concerning brushing technique, dental plaque was removed, and curettage was performed monthly until October 1997. However, these interventions were not effective, and ICE treatment (200 mg/day orally for 2 weeks, at intervals of 12 weeks) was given from 27 December 1997 until 18 December 1999. The interval between treatments was then extended from 12 weeks to 6 months.
The panoramic X-ray film taken 22 months after initiation of the ICE treatment indicated suppressed bone resorption of maxillary and mandibular alveolar bone, except for the maxillary second molar. The pocket depth, initially 4 -7 mm, had improved by 18 months and this was maintained at 42 months. A slight deterioration was observed in several teeth at 64 months, giving a situation similar to that at 22 months after initiation of the ICE treatment ( Table 1 ). The stability of the teeth was almost normal by 6 months (data not shown), and remained normal at 32 and 64 months after initiation of the ICE treatment ( Table 1) .
The mean alveolar bone density (Table 1 ) and the distribution curve of the brightness of the X-ray film of the alveolar bones ( Fig. 2A) showed increased density at 32 months and a slight decrease at 64 months after initiation of ICE treatment.
In summary, the patient, now aged 54 years, has received ICE treatment for > 64 months. There was a marked reduction in gingival inflammation and an initial increase in alveolar bone density followed by a decrease over the next 32 months.
PATIENT 2
On 4 March 1998, a 63-year-old woman presented with gingival inflammation and destruction of a prosthesis. The swollen abscess was incised, and antibiotics and anti-inflammatory analgesics were administered. Instruction on brushing technique was given, and elimination of dental plaque, root planning and curettage were performed. The prosthesis was replaced. ICE treatment (200 mg/day orally for 2 weeks, at intervals of 12 weeks) was initiated in April 1998. As previously reported, 1 comparison of panoramic X-ray films indicated improvement in the trabecular architecture, normalization of the bone contour line, appearance of lamina dura, and homogenization of the periodontal ligament space. The panoramic film at 18 months after initiation of ICE treatment showed inhibition of alveolar resorption in maxillary and mandibular bone, except for the maxillary right second molar. The depth of periodontal pockets was initially 4 -7 mm, but had decreased by 6 months (data not shown) and was 2 -3 mm at 22 months after initiation of ICE treatment. These beneficial effects have persisted after > 58 months of treatment (Table 1) . The teeth were more stable at 18 months and the improved condition, except for the right maxillary second molar, persisted > 58 months after initiation of treatment ( Table 1) .
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The mean alveolar bone density (Table 1 ) and the distribution curve of the brightness of the X-ray film of alveolar bone (Fig. 2B) showed increased density at 22 and Y Takaishi, T Ikeo, T Miki et al. 58 months after initiation of treatment.
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In summary, the now 69-year-old patient showed stabilization of the gingival tissues and increased density of the alveolar bone after > 58 months of ICE treatment.
PATIENT 3
A 48-year-old woman was seen in November 1997 with swelling of an abscess at the mandibular left first premolar and second molar, which was treated by incision. Although instruction on brushing technique was given, and elimination of plaque, root planning and curettage performed, the results were not satisfactory and the patient was given ICE treatment (200 mg/day orally for 2 weeks, at intervals of 12 weeks) from December 1997.
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Comparison of the initial panoramic X-ray film with those after 16 and 25 months of treatment showed normalization of the trabecular architecture, improvement in the bone contour line, appearance of lamina dura and homogenization of the periodontal ligament space. The depth of the periodontal pockets was initially 4 -7 mm; the effect of treatment became apparent at 6 months (data not shown), and the depth was 2 -3 mm at 16 months. All the teeth showed normal values at 60 months after initiation of treatment (Table 1) .
The mobility of the teeth reduced to normal values at 16 months, and has remained normal for > 60 months ( Table 1 ). The mean alveolar bone density (Table 1 ) and the distribution curve of the brightness of the X-ray film (Fig. 2C ) of alveolar bone indicated an increase in density to normal values at 16, 25 and 60 months after initiation of ICE treatment, although the increase was a little less at 60 months compared with that at 25 months.
In summary, the patient is now 53 years old, is still receiving ICE treatment and the alveolar tissues are in good condition.
PATIENT 4
A 59-year-old woman visited our clinic in December 1997. She complained of swelling of the maxillary right second molar due to periodontal abscess and mastication disability due to instability of all the teeth. Incision of the abscess and administration of antibiotics and analgesics ameliorated the symptoms.
Instruction on brushing technique was given, and elimination of plaque and curettage was performed regularly until January 1998. However, because swelling of the periodontal tissues and bleeding on brushing persisted, ICE treatment (200 mg/day orally for 2 weeks, at intervals of 12 weeks) was initiated in February 1998.
Comparison of serial panoramic X-ray films showed increased density at the sites of previously increased resorption. Gingival reddening and swelling, tooth instability and the depth of the periodontal pockets were reduced after initiation of ICE treatment (Table 1) . Gingival bleeding and impaired mastication were eliminated.
The initial pocket depth of 2 -5 mm decreased to 2 -3 mm after 16 months of ICE treatment ( Table 1 ). The improved levels of Alveolar bone density showed a marked increase at 16 and 26 months ( Table 1 and Fig. 2D ). There was a slight decrease in bone density at 49 months compared with that at 26 months; the depth of periodontal pockets also returned to pre-treatment levels, although the improved mobility score was maintained.
In summary, the patient is now aged 64 years and has been receiving ICE treatment for > 49 months. Good gingival and alveolar conditions are maintained.
SUMMARY
Four patients with periodontitis showed increased resorption of alveolar bone after intermittent cyclic treatment with etidronate in addition to usual dental therapy for 4 -5 years. In all cases there were significant increases in alveolar bone density, and significant reductions in the maxillary and mandibular mobility scores and the depth of the periodontal pockets (Table 1 ). Significant correlations were demonstrated between alveolar bone density and the mobility score or the depth of periodontal pockets in the mandibular and maxillary teeth ( Table 2) .
Alveolar bone density in three of the patients decreased following an initial increase. In post-menopausal women receiving daily alendronate 5 mg for the prevention of bone loss, lumbar BMD increased by 2.7% in the first year of treatment, but by only 0.8% in the second year. 9
Discussion
The present study showed that intermittent cyclic treatment with etidronate administered for 4 -5 years was effective in the treatment of alveolar bone loss associated with periodontitis.
There is at present no well-established method for assessing alveolar bone density, mainly because of the complex structure of alveolar bone. Jeffcoat and co-workers 2 reported a significant positive correlation between hip BMD and alveolar bone density measured from panoramic X-ray film of mandibles. Jonasson and colleagues 3 measured the BMD of the distal forearm and the cervical thickness of the mandibular alveolar process and found that forearm BMD significantly correlated with the difference between two measures of the thickness of the mandibular alveolar process in the region of the first premolar. The method presented here of measuring alveolar bone density by comparing the brightness in each square of a lattice using image-editing software can be used for the clinical evaluation and monitoring of the effect of treatment on resorption.
Wactawski-Wende 10 reported that women with severe osteoporosis are three times more likely to be edentulous compared with controls. A multicentre study was performed in Turkey to investigate the relationship between tooth loss and skeletal bone mass. 11 In this study, 1171 women with osteoporosis were divided into three groups according to the degree of tooth loss: group 1, edentulous; group 2, < 10 teeth remaining; and group 3, > 10 teeth remaining. The lumbar BMD in group 1 was significantly lower than that in groups 2 and 3. Furthermore, the lumbar bone mineral content in group 1 was also significantly lower than that in groups 2 and 3. Thus the edentulous state may be closely related to systemic osteoporosis. One risk factor for systemic osteoporosis is insufficient intake of calcium and other nutrients, and the edentulous state is also associated with insufficient intake of calcium. In addition, tooth loss is caused by a variety of diseases The present study demonstrates that etidronate treatment combined with ordinary dental therapy is effective in significantly increasing alveolar bone density 16 -32 months after initiation of treatment. Harris and associates 12 reported that etidronate therapy for post-menopausal osteoporosis maintained significant increases in spinal BMD for the first 2 years. An additional finding was that 3 years of etidronate therapy significantly decreased the vertebral fracture rate in patients at higher risk of fracture when compared with those not receiving etidronate. In their 7-year follow-up of post-menopausal women with osteoporosis receiving etidronate, Miller and colleagues 13 reported that spinal BMD was significantly increased after 104 weeks of treatment.
In the present study, teeth instability and the depth of the alveolar pockets were significantly reduced in all cases by ICE treatment. Since bacterial periodontitis is associated with increased production of cytokines related to bone metabolism, especially bone resorption, bisphosphonates should effectively suppress these cytokines. The bacteria that cause periodontitis can be easily detected using the benzoyl-DLarginine-naphthylamide test and by polymerase chain reaction measurement of pathogenic bacteria. 4 Osteoporosis and oestrogen deficiency are risk factors for alveolar bone density loss in post-menopausal women with a history of periodontitis. 14 Skeletal BMD is related to interproximal alveolar bone loss and, to a lesser extent, to clinical attachment loss, 15 and post-menopausal osteopenia is a risk indicator for periodontal disease. Bisphosphonates may be beneficial for both pathological processes.
In conclusion, a new method of measuring alveolar bone density is proposed. In the present study, alveolar bone density measured by this method correlated significantly with tooth instability and pocket depth associated with periodontitis. Intermittent treatment with etidronate was efficacious in increasing alveolar bone density in addition to the benefits in periodontitis previously reported. 
